Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215760063> ?p ?o ?g. }
- W3215760063 endingPage "5896" @default.
- W3215760063 startingPage "5896" @default.
- W3215760063 abstract "Angiogenesis has a direct stimulatory effect on tumor growth, duplication, invasion and metastatic development. A significant portion of conventional renal cell carcinomas are angiogenesis-dependent tumors and the pathways supporting this process have been thoroughly investigated over the last 20 years. As a consequence, many tyrosine kinase inhibitors (TKIs) (sunitinib, sorafenib, pazopanib, axitinib, and cabozantinib), one monoclonal antibody (bevacizumab), and two mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus) have been investigated and approved for the treatment of advanced or metastatic clear cell renal carcinoma (metastatic CCRC) in first-line, as well as second-line, therapy, with impressive results in progression-free survival and in the objective response rate compared with previously available therapies or placebo. Recently, a new type of drug has been approved for metastatic CCRC: immunomodulatory checkpoint inhibitors (ICIs), alone or in combination with TKIs. However, many questions and areas to be explored still remain with regard to clear cell renal carcinoma (CCRC) treatment: research on predictive biomarkers, the best patient selection, how to overcome the mechanisms of resistance, and the best sequence of therapies in daily clinical practice. This review focuses on the pharmacological properties and anticancer activities of these drugs. The toxicity profile and clinical limitations of these therapies are also discussed." @default.
- W3215760063 created "2021-12-06" @default.
- W3215760063 creator A5005250000 @default.
- W3215760063 creator A5032879117 @default.
- W3215760063 creator A5033483931 @default.
- W3215760063 creator A5068818328 @default.
- W3215760063 date "2021-11-24" @default.
- W3215760063 modified "2023-10-02" @default.
- W3215760063 title "Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results" @default.
- W3215760063 cites W1596261235 @default.
- W3215760063 cites W1974903851 @default.
- W3215760063 cites W1978139448 @default.
- W3215760063 cites W1982163978 @default.
- W3215760063 cites W1985804036 @default.
- W3215760063 cites W2008629746 @default.
- W3215760063 cites W2008825756 @default.
- W3215760063 cites W2008940139 @default.
- W3215760063 cites W2011810742 @default.
- W3215760063 cites W2018626410 @default.
- W3215760063 cites W2023952988 @default.
- W3215760063 cites W2025016054 @default.
- W3215760063 cites W2031298554 @default.
- W3215760063 cites W2035510806 @default.
- W3215760063 cites W2046507292 @default.
- W3215760063 cites W2056802932 @default.
- W3215760063 cites W2060118799 @default.
- W3215760063 cites W2099088585 @default.
- W3215760063 cites W2099752220 @default.
- W3215760063 cites W2100669312 @default.
- W3215760063 cites W2102575291 @default.
- W3215760063 cites W2105677187 @default.
- W3215760063 cites W2115005218 @default.
- W3215760063 cites W2115966993 @default.
- W3215760063 cites W2116949558 @default.
- W3215760063 cites W2123769946 @default.
- W3215760063 cites W2131798870 @default.
- W3215760063 cites W2136110110 @default.
- W3215760063 cites W2138129102 @default.
- W3215760063 cites W2140765540 @default.
- W3215760063 cites W2143761190 @default.
- W3215760063 cites W2143813821 @default.
- W3215760063 cites W2147186814 @default.
- W3215760063 cites W2152190103 @default.
- W3215760063 cites W2153331460 @default.
- W3215760063 cites W2153867442 @default.
- W3215760063 cites W2154670252 @default.
- W3215760063 cites W2155012968 @default.
- W3215760063 cites W2156242851 @default.
- W3215760063 cites W2156408558 @default.
- W3215760063 cites W2157262448 @default.
- W3215760063 cites W2161609794 @default.
- W3215760063 cites W2162424705 @default.
- W3215760063 cites W2166606169 @default.
- W3215760063 cites W2171620774 @default.
- W3215760063 cites W2222086386 @default.
- W3215760063 cites W2236874876 @default.
- W3215760063 cites W2415950182 @default.
- W3215760063 cites W2515839303 @default.
- W3215760063 cites W2531847064 @default.
- W3215760063 cites W2586120609 @default.
- W3215760063 cites W2606765235 @default.
- W3215760063 cites W2614019065 @default.
- W3215760063 cites W2637198528 @default.
- W3215760063 cites W2733280258 @default.
- W3215760063 cites W2752094938 @default.
- W3215760063 cites W2790729376 @default.
- W3215760063 cites W2792937256 @default.
- W3215760063 cites W2884027202 @default.
- W3215760063 cites W2913745075 @default.
- W3215760063 cites W2917677528 @default.
- W3215760063 cites W2943887705 @default.
- W3215760063 cites W2969541398 @default.
- W3215760063 cites W2983881420 @default.
- W3215760063 cites W2997290518 @default.
- W3215760063 cites W3014505556 @default.
- W3215760063 cites W3018979351 @default.
- W3215760063 cites W3046152668 @default.
- W3215760063 cites W3092634387 @default.
- W3215760063 cites W3131063362 @default.
- W3215760063 cites W3134949580 @default.
- W3215760063 cites W3178058903 @default.
- W3215760063 cites W4237816489 @default.
- W3215760063 cites W4252851641 @default.
- W3215760063 doi "https://doi.org/10.3390/cancers13235896" @default.
- W3215760063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34885006" @default.
- W3215760063 hasPublicationYear "2021" @default.
- W3215760063 type Work @default.
- W3215760063 sameAs 3215760063 @default.
- W3215760063 citedByCount "14" @default.
- W3215760063 countsByYear W32157600632022 @default.
- W3215760063 countsByYear W32157600632023 @default.
- W3215760063 crossrefType "journal-article" @default.
- W3215760063 hasAuthorship W3215760063A5005250000 @default.
- W3215760063 hasAuthorship W3215760063A5032879117 @default.
- W3215760063 hasAuthorship W3215760063A5033483931 @default.
- W3215760063 hasAuthorship W3215760063A5068818328 @default.
- W3215760063 hasBestOaLocation W32157600631 @default.
- W3215760063 hasConcept C121608353 @default.